BCM
CLBT icon

Bayesian Capital Management’s Cellebrite CLBT Stock Holding History

Bayesian Capital Management’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-45,682
Closed -$769K – 725
2024
Q3 		$769K Buy
+45,682
New +$678K 0.09% 283
2024
Q1 		– Sell
-13,200
Closed -$114K – 815
2023
Q4 		$114K Buy
+13,200
New +$103K 0.01% 648

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

Bayesian Capital Management's CLBT Position: Q4 2024 in Review

Bayesian Capital Management sold out of Cellebrite (CLBT) in Q4 2024, closing a stake of 45,682 shares — an estimated $769K sold.

Bayesian Capital Management first reported a position in CLBT in Q4 2023 and held it in 2 quarters. The position peaked at $769K in Q3 2024. 191 funds tracked by Wall St. Rank hold CLBT as of Q4 2024.

  • Bayesian Capital Management reported no remaining Cellebrite position as of Q4 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 45,682 Cellebrite shares in Q4 2024, an estimated $769K.
  • Bayesian Capital Management first reported a position in Cellebrite in Q4 2023 and held it in 2 quarters.
  • Bayesian Capital Management's Cellebrite position peaked at $769K in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Cellebrite as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.